While testing what is being called an “experimental cancer drug,” researchers took note that lab mice suffering from a rodent ...

Two trajectories of brain aging were identified in a cellular analysis of post-mortem brain tissue: one leading to ...

Shares of Athira Pharma tumbled after the company's trial of fosgonimeton for Alzheimer's disease patients failed to meet its primary endpoint. Shares plummeted 74% to 74 cents in after-hours trading ...

The Wasatch Back community is coming together for a meaningful cause: the annual Walk to End Alzheimer's. It’s a day dedicated to raising awareness and funds for Alzheimer's care, support and research ...

Athira Pharma (ATHA) stock cratered post-market after the company said a Phase 2/3 study of its drug Alzheimer’s drug candidate fosgonimeton failed to meet its primary endpoint.

Some researchers argue that the roles of social environment and personal choice have to be considered in order to make ...

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In ...

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

Aging is a complex biological process that also takes place in the brain. Researchers have discovered that the gene activity ...

Athira Pharma's trial of fosgonimeton for Alzheimer's disease patients failed to meet its primary endpoint. Bothell, Wash., biopharmaceutical company said Tuesday that neither the trial's primary ...

Study findings could have implications for treating muscle wasting sometimes associated with brain inflammation from ...